OPEN ACCESS Freely available online

Mycobacterial Diseases

ISSN: 2161-1068

Short Communication

Understanding the Immunological Basis of Latent Tuberculosis Infection

John Flynn*

Department of Medicine and Micobacterial Infection, Albert Einstein College of Medicine, Bronx, USA

DESCRIPTION

Tuberculosis (TB) is an ancient infectious disease caused by the bacteria *Mycobacterium tuberculosis*. While active TB is characterized by clinical symptoms and transmission, there exists another state known as Latent Tuberculosis Infection (LTBI). LTBI is a condition in which individuals carry the TB bacteria without displaying symptoms or being contagious. Understanding the immunological basis of LTBI is important for effective TB control strategies, as it illuminate on why some individuals remain asymptomatic carriers while others progress to active TB disease. This article delves into the intricate immunological mechanisms underlying LTBI [1].

The spectrum of TB infection

TB infection exists along a spectrum, with three primary states:

Latent Tuberculosis Infection (LTBI): In LTBI, individuals are infected with *M. tuberculosis*, but the bacteria are in a dormant state. These individuals do not exhibit symptoms, and they are not contagious. However, they carry the risk of developing active TB in the future, especially if their immune system weakens.

Active tuberculosis disease: Active TB occurs when the bacteria become active and cause clinical symptoms such as cough, fever, and weight loss. It can affect the lungs (pulmonary TB) or other parts of the body (extrapulmonary TB). Active TB is contagious and requires treatment.

Clearance of infection: Some individuals exposed to *M. tuberculosis* can successfully clear the infection through their immune response without developing LTBI or active TB. This outcome is relatively rare.

The immunological basis of LTBI

Cell-mediated immunity: The immune response to TB infection primarily involves cell-mediated immunity, orchestrated by T cells, particularly $CD4^+$ and $CD8^+$ T cells. Upon infection, Antigen-Presenting Cells (APCs) engulf *M. tuberculosis* and present its antigens to $CD4^+$ T cells. This interaction triggers a cascade of immune responses.

Granuloma formation: In LTBI, the immune system successfully contains *M. tuberculosis* within granulomas, which are organized clusters of immune cells. Granulomas serve as a barrier to prevent the spread of bacteria. They consist of infected macrophages, $CD4^+$ and $CD8^+$ T cells, and other immune cells.

Cytokines: Interferon-gamma (IFN-γ) is a critical cytokine in the immune response to TB. It is produced by $CD4^+$ T cells in response to *M. tuberculosis* antigens presented by APCs. IFN-γ activates macrophages, enabling them to better control the bacteria [2].

Quiescent bacteria: Within granulomas, M. tuberculosis enters a quiescent or dormant state, characterized by reduced metabolic activity. This dormant state helps the bacterium evade the immune system and antimicrobial drugs, contributing to LTBI's asymptomatic nature.

Immune evasion mechanisms: *M. tuberculosis* employs several mechanisms to evade immune responses. It can inhibit the fusion of phagosomes with lysosomes in macrophages, reducing bacterial killing. Additionally, it can alter its cell wall components to resist host immune mechanisms.

Balanced immune response: LTBI is often associated with a balanced immune response. While the immune system successfully contains the bacteria, it does not entirely eradicate them. Instead, a delicate equilibrium is maintained within the granulomas [3].

Risk factors for progression from LTBI to active TB

While LTBI is characterized by immune containment of *M. tuberculosis*, several risk factors can disrupt this equilibrium and lead to progression to active TB:

Immunosuppression: Conditions or treatments that weaken the immune system, such as HIV infection, immunosuppressive medications, and certain medical conditions (e.g., diabetes), increase the risk of LTBI reactivation.

Aging: Advancing age is associated with an increased risk of TB reactivation, likely due to age-related changes in the immune system [4].

Correspondence to: John Flynn, Department of Medicine and Micobacterial Infection, Albert Einstein College of Medicine, Bronx, USA E-mail: jflynn@aecom.yu.edu

Received: 03-Jul-2023, Manuscript No. MDTL-23-27262; **Editor assigned:** 05-Jul-2023, Pre QC No. MDTL-23-27262 (PQ); **Reviewed:** 19-Jul-2023, QC No. MDTL-23-27262; **Revised:** 26-Jul-2023, Manuscript No. MDTL-23-27262 (R); **Published:** 02-Aug-2023, DOI: 10.35248/2161-1068.23.13.376.

Citation: Flynn J (2023) Understanding the Immunological Basis of Latent Tuberculosis Infection. Mycobact Dis. 13:376.

Malnutrition: Poor nutrition can weaken the immune system, making individuals more susceptible to TB reactivation.

Stress: Psychological and physiological stress can weaken the immune response, potentially increasing the risk of LTBI reactivation.

Substance abuse: Substance abuse, including alcohol and drug abuse, can impair immune function, making individuals more vulnerable to TB progression.

Environmental factors: Close and prolonged contact with individuals with active TB disease, especially in crowded or poorly ventilated settings, can increase the risk of LTBI reactivation.

TB control strategies

Understanding the immunological basis of LTBI is important for developing effective TB control strategies:

LTBI screening: Identifying individuals with LTBI, especially those at high risk of progression, is essential. Screening tools, such as the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs), are used to detect LTBI [5].

Preventive therapy: Individuals with LTBI, particularly those at higher risk of progression, can benefit from preventive therapy. Isoniazid (INH) is commonly used for this purpose.

TB vaccination: The Bacillus Calmette-Gurin (BCG) vaccine, which provides partial protection against TB, is administered in many countries, particularly to infants. However, it does not prevent LTBI.

Improved diagnostic tools: Advancements in TB diagnostic tools, such as molecular assays and point-of-care tests, are enhancing our ability to detect both LTBI and active TB more accurately and quickly.

Targeted interventions: TB control programs should prioritize high-risk populations for LTBI screening and preventive therapy, addressing social determinants of health and providing support to individuals at risk.

CONCLUSION

Understanding the immunological basis of latent tuberculosis infection is fundamental to controlling the global TB epidemic. While LTBI is characterized by the successful containment of *Mycobacterium tuberculosis*, several factors can disrupt this equilibrium, leading to the progression to active TB disease. Comprehensive TB control strategies encompass LTBI screening, preventive therapy, vaccination, and improved diagnostic tools. As research in immunology and TB progresses, We persist in acquiring knowledge that will mold more efficient interventions, ultimately contributing to the goal of eradicating TB as a global health menace.

REFERENCES

1. Seshadri C, Sedaghat N, Campo M, Peterson G, Wells RD, Olson GS, et al. Transcriptional networks are associated with resistance to *Mycobacterium tuberculosis* infection. PLoS one 2017;12(4): e0175844.
2. Wang C, Yang S, Sun G, Tang X, Lu S, et al. Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS one. 2011;6(10):e25832.
3. Pai M, Behr M. Latent *Mycobacterium tuberculosis* infection and interferon-gamma release assays. Microbiol Spectr. 2016;4(5):4-5.
4. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, et al. Incipient and subclinical tuberculosis: A clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31(4):10-128.
5. Ruhwald M, Ravn P. Biomarkers of latent TB infection. Expert Rev Respir Med. 2009;3(4):387-401.